AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...

It hasn't been the best quarter for AbbVie Inc. (NYSE:ABBV) shareholders, since the share price has fallen 11% in that time. But at least the stock is up over the last five years.

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

Making Sense of Earnings Expectations for 2025 Q2 and Beyond The start of Q2 coincided with heightened tariff uncertainty following the punitive April 2 nd tariff announcements.

AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com.

Everything to Know about Macro and Markets Stock indexes fell on Friday, reversing mid‑week gains and closing in the red, as the tariff theme came ...

President Trump is amping up trade threats, again unveiling a new batch of letters to country leaders outlining tariffs on ...